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ABSTRACT - Cholesterol determinations in morning urine samples were taken in 235 selected 
patients with a positive test for microscopic hematuria. Values ranged from 0.2 to 76.0 mg (median 
5.5) in 23 patients with urologic malignancies and from 0.1 to 33.4 mg (median 1 .l) in 38 patients with 
various benign diseases of the kidney or urogenital tract. In the 28 patients with urinary tract 
infections and 146 subjects without evidence of disorders of the kidney and the urogenital system, 
urinary cholesterol excretion was usually normal (0.1 to 1.9 mg; median 0.35). Using 1 .O mg urinary 
cholesterol per morning urine as a cutoff point, sensitivity for urologic carcinomas is about 80 per 
cent with a comparable high speci$city of 90 per cent. Therefore, subsequent measurements of 
urinary cholesterol in populations with microscopic hematuria could define two groups, one with high 
prevalence and one with low prevalence of urologic malignancies. The less complicated calorimetric 
instead of gas-liquid chromatographic determination of urinary cholesterol can be recommended as a 
screening test for urologic carcinomas in populations with microscopic hematuria. 
Since the event of the polarizing microscope, 
birefringent or anisotropic crystals are well rec- 
ognized components in the urinary sediment of 
patients with a variety of diseases, especially the 
nephrotic syndrome. l-3 This anisotopic material 
is apparently composed largely of cholesterol es- 
ters with a smaller proportion of free choles- 
terol. 4 However, the quantitative determination 
of cholesterol in urine has received compara- 
tively little attention. Reports in the literature5-‘6 
have indicated that patients with benign and 
malignant diseases of the kidney or the uro- 
genital tract frequently have marked elevations 
of cholesterol in their urine. Based on these 
studies it was suggested that the determination 
of urinary cholesterol may be of possible value in 
the diagnosis of urogenital carcinomas, especially 
of the prostate, kidney, and bladder. 
The objective of a recent study was to deter- 
mine whether or not this method could be used 
as a screening test in large numbers of patients. ” 
A high predictive value (0.23) of a positive uri- 
nary cholesterol test result (exceeding the upper 
3 SD limit) and the presence of urologic neo- 
plasms in males was apparently due to patient 
selection. Therefore, because of the low preva- 
lence of urologic carcinomas in an average popu- 
lation, this method has not been recommended 
as a primary screening test. 
The present study was carried out to investi- 
gate the possibility of whether urinary choles- 
terol determinations could be successfully 
applied in preselected populations with an in- 
creased prevalence of urologic carcinomas due to 
a positive test result for microscopic hematuria. 
Material and Methods 
The study included a total of 235 patients, 119 
males with an age range of fifty to eighty-two 
years (median 63.4) and 116 females with an age 
range of fifty to seventy-nine years (median 
58.6). Criteria for selection were an age above 
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TABLE I. Urina y cholesterol in patients with 
urologic carcinomas and microscopic hematuria 
Diagnosis 
Tumor Cholesterol (Mg)/ 
Stage/Grade Morning Urine 
Carcinoma of 
bladder 
Carcinoma of 
prostate 
Carcinoma of 
kidney 
13.1 
11.1 
8.6 
6.3 
6.3 
4.3 
1.4 
1.2 
12.3 
1.3 
0.7 
0.8 
0.4 
14.2 
76.0 
2.4 
0.2 
5.7 
8.8 
52.3 
2.8 
0.9 
5.5 
fifty years and a positive test result for mi- 
croscopic hematuria in the urinary sediment. 
These data were provided by the central institute 
of clinical chemistry and read from computer 
charts. The diagnoses of the investigated patients 
were usually not known at the date of the urinary 
cholesterol analyses which were performed ex- 
clusively on morning urine samples. Patients 
with urethral catheters, suprapubic fistula, or 
macroscopic hematuria were excluded from the 
study. 
Analysis of urinary cholesterol 
Urinary cholesterol was analyzed in 2 by l-ml 
aliquots of morning urine samples and expressed 
as mg cholesterol/sample considering the total 
volume. After extraction with 8 ml chloroform/ 
methanol(3: 1) and centrifugation, 5.0 ml 
chloroform were removed and dried under a 
stream of nitrogen. 
The residue was hydrolyzed with 0.5 ml 
ethanolic 0.5 N KOH at 60” C for sixty minutes 
and reextracted with 6 ml n-hexane. A total of 5 
ml extract was used for subsequent gas-liquid 
chromatography. The dried residue was dis- 
solved in 0.1 ml of the internal standard solution 
(10 mg 4_androstenedione/dl iso-octane). Two to 
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3 ~1 were injected on a 1.80 m, l%-XE-60 col- 
umn, id. 2 mm, temp. const. 220” C, and meas- 
ured by flame ionization detectors. 
Quantitation was performed due to the peak 
height ratio, since alterations of cholesterol/4- 
androstenedione concentrations gave a linear re- 
sponse. The specificity of the method was 
confirmed by simultaneous mass-fragmento- 
metric analysis in selected samples. Using this 
method an intra-assay variance of 5.6 per cent 
and an inter-assay variance of 10.4 per cent was 
calculated with an average recovery exceeding 90 
per cent. A less complicated calorimetric deter- 
mination of cholesterol in the dried hexane 
extracts is possible but was not used in this 
study. 
Results 
After completing the urinary cholesterol 
analysis, the evaluation of the clinical records re- 
vealed the presence of known urologic malignan- 
cies in 23 of 235 selected patients with a preva- 
lence of 15.9 per cent in males and 3.4 per cent 
in females. Data on these patients including 
tumor stage and grade and the results of urinary 
cholesterol determinations are illustrated in 
Table I. In 38 patients various benign diseases of 
the kidney and the urogenital tract were present, 
and in 28 patients infections of the-bladder had 
been diagnosed. In 146 patients with mi- 
croscopic hematuria, clinical records revealed no 
evidence of diseases of the urogenital system. 
They consisted of 34 with endocrine and 
metabolic disorders, 43 with cardiovascular, :41 
TABLE II. Vrina y cholesterol in patients with 
benign diseases of kidney and urogenital tract or 
other internal disorders and microscopic hemuturia 
Diagnosis 
Adenoma of kidney 
Adenoma of prostate 
Urolithiasis 
Renal insufficiency 
(cause unknown) 
Nephrotic syndrome 
Renal cyst 
Glomerular, tubular 
and vascular dis- 
eases of kidney 
Infections of bladder 
Other internal 
diseases 
Cholesterol (Mg)/ 
Morning Urine 
n Range Median 
1 1.8 1.8 
3 0.2-4.4 2.3 
12 0.1-9.6 1.1 
5 0.2-7.2 0.9 
4 0.3-33.4 4.2 
3 0.1-10.4 0.8 
10 0.2-4.4 0.6 
28 0.1-1.7 0.4 
146 0.1-1.9 0.3 
with gastrointestinal, 15 with respiratory, and 13 
with hematopoietic diseases. The ranges and 
medians of the urinary cholesterol determina- 
tions in several groups of these patients are pre- 
sented in Table II. 
The correlation of sensitivity and specificity for 
urologic carcinomas at various cutoff points from 
0.1 to 5.0 mg cholesterol in morning urine is 
given in Figure 1. 
Comment 
Hyperexcretion of urinary cholesterol in asso- 
ciation with urologic malignancies has been ob- 
served in several studies and was thought to be of 
value in the diagnosis of these diseases.5-16 In a 
prior study, positive test results, using the upper 
3 SD limit as cutoff point, have been obtained in 
13 of 430 male patients and in 9 of 545 female 
patients above fifty years old.” There was no 
evidence of neoplasias or diseases of the kidneys 
and urogenital tract at the date of the urinary 
cholesterol analysis. 
After further investigation, 2 carcinomas of the 
bladder and 1 carcinoma of the kidney were 
diagnosed in the male group while in female pa- 
tients no malignancies could be detected. In 
most cases, however, nonmalignant diseases of 
the kidney and the urogenital tract seemed to be 
responsible for the measured increments of uri- 
nary cholesterol. The high predictive value (0.23) 
of a positive urinary cholesterol test result, and 
the presence of urologic neoplasms in the male 
group, was obviously due to patient selection, 
since comparable results could not be expected 
in a normal population as well as in cancer 
screening. 
Urinary testing for occult blood, usually by 
microscopic analysis, is a simple method which 
will result in an increased prevalence of urologic 
carcinomas in the average population. This 
method has a diagnostic sensitivity of about 45 to 
70 per cent for these malignancies and increases 
the low prevalence from about 0.1 to 1 to 2 per 
cent in males and from 0.02-0.03 to 0.2-0.3 per 
cent in females above forty years old. The low 
predictive value of a positive test for occult blood 
(0.002-0.02) and the presence of urologic malig- 
nancies clearly diminish the value of this method 
as an effective screening test. 
The presented results demonstrated that sub- 
sequent measurements of urinary cholesterol in 
populations with microscopic hematuria could be 
advantageous in defining high-risk and low-risk 
groups for urologic carcinomas. For the given 
problem, the most practical cutoff value for the 
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FIGURE 1. Correlation of sensitivity and specijkity 
of cholesterol in morning urine for urologic car- 
cinomas in population with microscopic hematuria. 
urinary cholesterol method is 1.0 mg/morning 
urine. At this cutoff point, sensitivity for car- 
cinomas of prostate, kidney, or bladder with 
associated microscopic hematuria is about 80 per 
cent with a comparable high specificity of 90 per 
cent. Therefore, subsequent measurements of 
urinary cholesterol in populations with mi- 
croscopic hematuria, which could be revealed in 
cancer screening, would increase the prevalence 
of urologic carcinomas in positive cases (ex- 
ceeding 1 mg cholesterol/morning urine sample) 
about eightfold. 
The less expensive and complicated enzymatic 
assay of urinary cholesterol in the dried hexane 
extracts can be recommended as a secondary 
screening test for urologic carcinomas in selected 
populations with microscopic hematuria. 
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